Emerging therapeutics in the management of connective tissue disease. Part II: Dermatomyositis and scleroderma

The management of connective tissue diseases is dramatically evolving with the advent of biologics and novel oral systemic therapeutics. Despite involvement in the care of these complex patients, there is a knowledge gap in the field of dermatology regarding these emerging agents. The second article...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Academy of Dermatology 2022-07, Vol.87 (1), p.21-38
Main Authors: Kodumudi, Vijay, Bibb, Lorin A., Adalsteinsson, Jonas A., Shahriari, Neda, Skudalski, Lauren, Santiago, Sueheidi, Grant-Kels, Jane M., Lu, Jun
Format: Article
Language:English
Subjects:
clinical trials
clinically amyopathic dermatomyositis
current management dermatomyositis
juvenile dermatomyositis
scleroderma
systemic sclerosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c356t-88ee595d84d4901a646322d9246d05649ec15a9927333033acebcf4d1ceee6113
cites cdi_FETCH-LOGICAL-c356t-88ee595d84d4901a646322d9246d05649ec15a9927333033acebcf4d1ceee6113
container_end_page 38
container_issue 1
container_start_page 21
container_title Journal of the American Academy of Dermatology
container_volume 87
creator Kodumudi, Vijay
Bibb, Lorin A.
Adalsteinsson, Jonas A.
Shahriari, Neda
Skudalski, Lauren
Santiago, Sueheidi
Grant-Kels, Jane M.
Lu, Jun
description The management of connective tissue diseases is dramatically evolving with the advent of biologics and novel oral systemic therapeutics. Despite involvement in the care of these complex patients, there is a knowledge gap in the field of dermatology regarding these emerging agents. The second article in this continuing medical education series discusses new and emerging therapeutics for dermatomyositis and scleroderma that target cells, intracellular signaling pathways, and cytokines.
doi_str_mv 10.1016/j.jaad.2021.12.068
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2633846884</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0190962222003279</els_id><sourcerecordid>2633846884</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-88ee595d84d4901a646322d9246d05649ec15a9927333033acebcf4d1ceee6113</originalsourceid><addsrcrecordid>eNp9kE1rGzEQhkVpqV2nf6CHoGMvu9XXalehl-CkqSHQHpqzkKVZR8YrOZI24H-fXZzmmNMwzPO-MA9C3yipKaHyx77eG-NqRhitKauJ7D6gJSWqrWTbtR_RklBFKiUZW6AvOe8JIUrw9jNa8GYKtW27ROF2gLTzYYfLIyRzhLF4m7EP844HE8wOBggFxx7bGALY4p8BF5_zCNj5DCZDjf-aVPBmc4VvIA2mxOEUs58gbILD2R4gRTdfLtCn3hwyfH2dK_Tw6_bf-nd1_-dus76-ryxvZKm6DqBRjeuEE4pQI4XkjDnFhHSkkUKBpY1RirWcc8K5sbC1vXDUAoCklK_Q93PvMcWnEXLRg88WDgcTII5ZM8l5J2TXiQllZ9SmmHOCXh-TH0w6aUr07Fnv9exZz541ZXryPIUuX_vH7QDuLfJf7AT8PAMwffnsIelsPQQLzqfJoXbRv9f_AvtZj08</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2633846884</pqid></control><display><type>article</type><title>Emerging therapeutics in the management of connective tissue disease. Part II: Dermatomyositis and scleroderma</title><source>Elsevier</source><creator>Kodumudi, Vijay ; Bibb, Lorin A. ; Adalsteinsson, Jonas A. ; Shahriari, Neda ; Skudalski, Lauren ; Santiago, Sueheidi ; Grant-Kels, Jane M. ; Lu, Jun</creator><creatorcontrib>Kodumudi, Vijay ; Bibb, Lorin A. ; Adalsteinsson, Jonas A. ; Shahriari, Neda ; Skudalski, Lauren ; Santiago, Sueheidi ; Grant-Kels, Jane M. ; Lu, Jun</creatorcontrib><description>The management of connective tissue diseases is dramatically evolving with the advent of biologics and novel oral systemic therapeutics. Despite involvement in the care of these complex patients, there is a knowledge gap in the field of dermatology regarding these emerging agents. The second article in this continuing medical education series discusses new and emerging therapeutics for dermatomyositis and scleroderma that target cells, intracellular signaling pathways, and cytokines.</description><identifier>ISSN: 0190-9622</identifier><identifier>EISSN: 1097-6787</identifier><identifier>DOI: 10.1016/j.jaad.2021.12.068</identifier><identifier>PMID: 35202777</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>clinical trials ; clinically amyopathic dermatomyositis ; current management dermatomyositis ; juvenile dermatomyositis ; scleroderma ; systemic sclerosis</subject><ispartof>Journal of the American Academy of Dermatology, 2022-07, Vol.87 (1), p.21-38</ispartof><rights>2022 American Academy of Dermatology, Inc.</rights><rights>Copyright © 2022. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-88ee595d84d4901a646322d9246d05649ec15a9927333033acebcf4d1ceee6113</citedby><cites>FETCH-LOGICAL-c356t-88ee595d84d4901a646322d9246d05649ec15a9927333033acebcf4d1ceee6113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35202777$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kodumudi, Vijay</creatorcontrib><creatorcontrib>Bibb, Lorin A.</creatorcontrib><creatorcontrib>Adalsteinsson, Jonas A.</creatorcontrib><creatorcontrib>Shahriari, Neda</creatorcontrib><creatorcontrib>Skudalski, Lauren</creatorcontrib><creatorcontrib>Santiago, Sueheidi</creatorcontrib><creatorcontrib>Grant-Kels, Jane M.</creatorcontrib><creatorcontrib>Lu, Jun</creatorcontrib><title>Emerging therapeutics in the management of connective tissue disease. Part II: Dermatomyositis and scleroderma</title><title>Journal of the American Academy of Dermatology</title><addtitle>J Am Acad Dermatol</addtitle><description>The management of connective tissue diseases is dramatically evolving with the advent of biologics and novel oral systemic therapeutics. Despite involvement in the care of these complex patients, there is a knowledge gap in the field of dermatology regarding these emerging agents. The second article in this continuing medical education series discusses new and emerging therapeutics for dermatomyositis and scleroderma that target cells, intracellular signaling pathways, and cytokines.</description><subject>clinical trials</subject><subject>clinically amyopathic dermatomyositis</subject><subject>current management dermatomyositis</subject><subject>juvenile dermatomyositis</subject><subject>scleroderma</subject><subject>systemic sclerosis</subject><issn>0190-9622</issn><issn>1097-6787</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kE1rGzEQhkVpqV2nf6CHoGMvu9XXalehl-CkqSHQHpqzkKVZR8YrOZI24H-fXZzmmNMwzPO-MA9C3yipKaHyx77eG-NqRhitKauJ7D6gJSWqrWTbtR_RklBFKiUZW6AvOe8JIUrw9jNa8GYKtW27ROF2gLTzYYfLIyRzhLF4m7EP844HE8wOBggFxx7bGALY4p8BF5_zCNj5DCZDjf-aVPBmc4VvIA2mxOEUs58gbILD2R4gRTdfLtCn3hwyfH2dK_Tw6_bf-nd1_-dus76-ryxvZKm6DqBRjeuEE4pQI4XkjDnFhHSkkUKBpY1RirWcc8K5sbC1vXDUAoCklK_Q93PvMcWnEXLRg88WDgcTII5ZM8l5J2TXiQllZ9SmmHOCXh-TH0w6aUr07Fnv9exZz541ZXryPIUuX_vH7QDuLfJf7AT8PAMwffnsIelsPQQLzqfJoXbRv9f_AvtZj08</recordid><startdate>20220701</startdate><enddate>20220701</enddate><creator>Kodumudi, Vijay</creator><creator>Bibb, Lorin A.</creator><creator>Adalsteinsson, Jonas A.</creator><creator>Shahriari, Neda</creator><creator>Skudalski, Lauren</creator><creator>Santiago, Sueheidi</creator><creator>Grant-Kels, Jane M.</creator><creator>Lu, Jun</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20220701</creationdate><title>Emerging therapeutics in the management of connective tissue disease. Part II: Dermatomyositis and scleroderma</title><author>Kodumudi, Vijay ; Bibb, Lorin A. ; Adalsteinsson, Jonas A. ; Shahriari, Neda ; Skudalski, Lauren ; Santiago, Sueheidi ; Grant-Kels, Jane M. ; Lu, Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-88ee595d84d4901a646322d9246d05649ec15a9927333033acebcf4d1ceee6113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>clinical trials</topic><topic>clinically amyopathic dermatomyositis</topic><topic>current management dermatomyositis</topic><topic>juvenile dermatomyositis</topic><topic>scleroderma</topic><topic>systemic sclerosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kodumudi, Vijay</creatorcontrib><creatorcontrib>Bibb, Lorin A.</creatorcontrib><creatorcontrib>Adalsteinsson, Jonas A.</creatorcontrib><creatorcontrib>Shahriari, Neda</creatorcontrib><creatorcontrib>Skudalski, Lauren</creatorcontrib><creatorcontrib>Santiago, Sueheidi</creatorcontrib><creatorcontrib>Grant-Kels, Jane M.</creatorcontrib><creatorcontrib>Lu, Jun</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Academy of Dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kodumudi, Vijay</au><au>Bibb, Lorin A.</au><au>Adalsteinsson, Jonas A.</au><au>Shahriari, Neda</au><au>Skudalski, Lauren</au><au>Santiago, Sueheidi</au><au>Grant-Kels, Jane M.</au><au>Lu, Jun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Emerging therapeutics in the management of connective tissue disease. Part II: Dermatomyositis and scleroderma</atitle><jtitle>Journal of the American Academy of Dermatology</jtitle><addtitle>J Am Acad Dermatol</addtitle><date>2022-07-01</date><risdate>2022</risdate><volume>87</volume><issue>1</issue><spage>21</spage><epage>38</epage><pages>21-38</pages><issn>0190-9622</issn><eissn>1097-6787</eissn><abstract>The management of connective tissue diseases is dramatically evolving with the advent of biologics and novel oral systemic therapeutics. Despite involvement in the care of these complex patients, there is a knowledge gap in the field of dermatology regarding these emerging agents. The second article in this continuing medical education series discusses new and emerging therapeutics for dermatomyositis and scleroderma that target cells, intracellular signaling pathways, and cytokines.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35202777</pmid><doi>10.1016/j.jaad.2021.12.068</doi><tpages>18</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0190-9622
ispartof Journal of the American Academy of Dermatology, 2022-07, Vol.87 (1), p.21-38
issn 0190-9622
1097-6787
language eng
recordid cdi_proquest_miscellaneous_2633846884
source Elsevier
subjects clinical trials
clinically amyopathic dermatomyositis
current management dermatomyositis
juvenile dermatomyositis
scleroderma
systemic sclerosis
title Emerging therapeutics in the management of connective tissue disease. Part II: Dermatomyositis and scleroderma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T11%3A08%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Emerging%20therapeutics%20in%20the%20management%20of%20connective%20tissue%20disease.%20Part%20II:%20Dermatomyositis%20and%20scleroderma&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Dermatology&rft.au=Kodumudi,%20Vijay&rft.date=2022-07-01&rft.volume=87&rft.issue=1&rft.spage=21&rft.epage=38&rft.pages=21-38&rft.issn=0190-9622&rft.eissn=1097-6787&rft_id=info:doi/10.1016/j.jaad.2021.12.068&rft_dat=%3Cproquest_cross%3E2633846884%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c356t-88ee595d84d4901a646322d9246d05649ec15a9927333033acebcf4d1ceee6113%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2633846884&rft_id=info:pmid/35202777&rfr_iscdi=true